{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:25:40Z","timestamp":1788791140565,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this integrated analysis is to evaluate the long-term safety and tolerability of ixekizumab in adults with psoriasis, PsA and axial SpA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Integrated safety data from 21 clinical trials are presented by indication in patients who received at least one dose of ixekizumab. Adverse events (AEs) and treatment-emergent adverse events (TEAEs) adjusted incidence rates (IRs) per 100 patient-years (PY) up to 5\u2009years\u2019 exposure are reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 8228 patients with an ixekizumab exposure of 20\u00a0895.9 PY were included in this analysis. The most common TEAEs were nasopharyngitis, upper respiratory tract infection and injection-site reactions. Across populations, IRs were low for AEs leading to discontinuation (IRs \u22645.1 per 100 PY), serious AEs (IRs \u22646.0 per 100 PY) and death (IRs \u22640.3 per 100 PY). The most reported TEAEs of special interest were infections (IRs \u226435.8 per 100 PY). Patients rarely reported malignancies (IR \u22640.8), IBD including ulcerative colitis and Crohn\u2019s disease (IR \u22640.8) and major adverse cardiovascular events (IR \u22640.5). TEAEs were most commonly reported the first 2\u2009years of exposure with ixekizumab and IR decreased over the years (infections, injection-site reactions and depression) or remained constant over the entire treatment period (serious infections, major adverse cardiovascular events, malignancies and IBD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This long-term analysis on the safety of ixekizumab was consistent with previously published reports and did not show any new safety signals. The safety profile and tolerability reported in this integrated analysis remained consistent with the known safety profile for ixekizumab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa189","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T19:11:43Z","timestamp":1585941103000},"page":"3834-3844","source":"Crossref","is-referenced-by-count":65,"title":["Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials"],"prefix":"10.1093","volume":"59","author":[{"given":"Mark C","family":"Genovese","sequence":"first","affiliation":[{"name":"Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n Medica de Investigaci\u00f3n, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A","family":"Papp","sequence":"additional","affiliation":[{"name":"Clinical Research and Probity Medical Research Inc., Waterloo, and the University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[{"name":"Azienda USL-IRCCS di Reggio Emilia, Universit\u00e0 di Modena e Reggio Emilia, Modena, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Schwartzman","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Hospital for Special Surgery, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Gallo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Patel","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R","family":"Lisse","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andris","family":"Kronbergs","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyi Liu","family":"Leage","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Adams","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mount Sinai Hospital, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"2021092202321116600_keaa189-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2021092202321116600_keaa189-B2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14712598.2018.1410133","article-title":"Ixekizumab: an anti-IL-17A monoclonal antibody for the treatment of psoriatic arthritis","volume":"18","author":"Toussirot","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2021092202321116600_keaa189-B3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"2021092202321116600_keaa189-B4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"2021092202321116600_keaa189-B5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J Inflamm Res"},{"key":"2021092202321116600_keaa189-B6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.15242","article-title":"Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials","volume":"33","author":"Langley","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021092202321116600_keaa189-B7","first-page":"133","article-title":"Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure","volume":"10","author":"Armstrong"},{"key":"2021092202321116600_keaa189-B8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2016.09.026","article-title":"Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data","volume":"76","author":"Strober","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2021092202321116600_keaa189-B9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res (Hoboken"},{"key":"2021092202321116600_keaa189-B10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","article-title":"Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis","volume":"22","author":"Combe","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2021092202321116600_keaa189-B11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: which therapy for which patient: focus on special populations and chronic infections","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2021092202321116600_keaa189-B12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2021092202321116600_keaa189-B13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"2021092202321116600_keaa189-B14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021092202321116600_keaa189-B15","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"2021092202321116600_keaa189-B16","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2021092202321116600_keaa189-B17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021092202321116600_keaa189-B18","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021092202321116600_keaa189-B19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.12670","article-title":"Psoriasis and smoking: a systematic review and meta-analysis","volume":"170","author":"Armstrong","year":"2014","journal-title":"Br J Dermatol"},{"key":"2021092202321116600_keaa189-B20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2014-206824","article-title":"On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trondelag Health Study","volume":"75","author":"Gulati","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021092202321116600_keaa189-B21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/rheumatology\/ket343","article-title":"Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study","volume":"53","author":"Dubreuil","year":"2014","journal-title":"Rheumatology (Oxford"},{"key":"2021092202321116600_keaa189-B22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12891-015-0532-3","article-title":"Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation","volume":"16","author":"Heslinga","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"2021092202321116600_keaa189-B23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1874312901711010053","article-title":"Axial spondyloarthritis and cigarette smoking","volume":"11","author":"Kaut","year":"2017","journal-title":"Open Rheumatol J"},{"key":"2021092202321116600_keaa189-B24","first-page":"612","article-title":"Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis","volume":"31","author":"Papagoras","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2021092202321116600_keaa189-B25","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.jid.2016.01.040","article-title":"A highly sensitive and drug-tolerant anti-drug antibody screening assay for ixekizumab using affinity capture elution","volume":"136","author":"Muram","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2021092202321116600_keaa189-B26","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jid.2016.03.035","article-title":"Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis","volume":"136","author":"Yiu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2021092202321116600_keaa189-B27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br J Dermatol"},{"key":"2021092202321116600_keaa189-B28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nbt0612-475","article-title":"Anti-IL-17 mAbs herald new options in psoriasis","volume":"30","author":"Garber","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2021092202321116600_keaa189-B29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1468-3083.2008.03031.x","article-title":"Psoriasis associated with ulcerative colitis and Crohn\u2019s disease","volume":"23","author":"Cohen","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021092202321116600_keaa189-B30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2009.02.015","article-title":"The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis","volume":"61","author":"Makredes","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2021092202321116600_keaa189-B31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjd.14528","article-title":"Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study","volume":"175","author":"Egeberg","year":"2016","journal-title":"Br J Dermatol"},{"key":"2021092202321116600_keaa189-B32","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/annrheumdis-2014-205253","article-title":"The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021092202321116600_keaa189-B33","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn\u2019s disease in US women","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021092202321116600_keaa189-B34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2340\/00015555-0770","article-title":"Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany","volume":"90","author":"Augustin","year":"2010","journal-title":"Acta Derm Venereol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/12\/3834\/40425032\/keaa189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/12\/3834\/40425032\/keaa189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T02:33:30Z","timestamp":1632278010000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/12\/3834\/5843844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,5,25]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa189","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,5,25]]}}}